Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Mol Microbiol ; 92(1): 194-211, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24517327

RESUMO

In Mycobacterium tuberculosis the decaprenyl-phospho-d-arabinofuranose (DPA) pathway is a validated target for the drugs ethambutol and benzothiazinones. To identify other potential drug targets in the pathway, we generated conditional knock-down mutants of each gene involved using the TET-PIP OFF system. dprE1, dprE2, ubiA, prsA, rv2361c, tkt and rpiB were confirmed to be essential under non-permissive conditions, whereas rv3807c was not required for survival. In the most vulnerable group, DprE1-depleted cells died faster in vitro and intracellularly than those lacking UbiA and PrsA. Downregulation of DprE1 and UbiA resulted in similar phenotypes, namely swelling of the bacteria, cell wall damage and lysis as observed at the single cell level, by real time microscopy and electron microscopy. By contrast, depletion of PrsA led to cell elongation and implosion, which was suggestive of a more pleiotropic effect. Drug sensitivity assays with known DPA-inhibitors supported the use of conditional knock-down strains for target-based whole-cell screens. Together, our work provides strong evidence for the vulnerability of all but one of the enzymes in the DPA pathway and generates valuable tools for the identification of lead compounds targeting the different biosynthetic steps. PrsA, phosphoribosyl-pyrophosphate synthetase, appears to be a particularly attractive new target for drug discovery.


Assuntos
Arabinose/análogos & derivados , Genes Bacterianos , Mycobacterium tuberculosis/crescimento & desenvolvimento , Transdução de Sinais , Antibacterianos/farmacologia , Arabinose/antagonistas & inibidores , Arabinose/biossíntese , Proteínas de Bactérias , Linhagem Celular Tumoral , Parede Celular/ultraestrutura , Regulação da Expressão Gênica/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Genes Bacterianos/efeitos dos fármacos , Genes Essenciais/efeitos dos fármacos , Humanos , Lipoproteínas , Macrófagos/microbiologia , Proteínas de Membrana , Microscopia , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/ultraestrutura , Transdução de Sinais/efeitos dos fármacos
2.
Bioorg Med Chem Lett ; 25(16): 3234-45, 2015 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-26087937

RESUMO

Whole cell based screens to identify hits against Mycobacterium tuberculosis (Mtb), carried out under replicating and non-replicating (NRP) conditions, resulted in the identification of multiple, novel but structurally related spiropiperidines with potent antitubercular properties. These compounds could be further classified into three classes namely 3-(3-aryl-1,2,4-oxadiazol-5-yl)-1'-alkylspiro[indene-1,4'-piperidine] (abbr. spiroindenes), 4-(3-aryl-1,2,4-oxadiazol-5-yl)-1'-alkylspiro[chromene-2,4'-piperidine] (abbr. spirochromenes) and 1'-benzylspiro[indole-1,4'-piperidin]-2(1H)-one (abbr. spiroindolones). Spiroindenes showed ⩾ 4 log10 kill (at 2-12 µM) on replicating Mtb, but were moderately active under non replicating conditions. Whole genome sequencing efforts of spiroindene resistant mutants resulted in the identification of I292L mutation in MmpL3 (Mycobacterial membrane protein Large), required for the assembly of mycolic acid into the cell wall core of Mtb. MIC modulation studies demonstrated that the mutants were cross-resistant to spirochromenes but not to spiroindolones. This Letter describes lead identification efforts to improve potency while reducing the lipophilicity and hERG liabilities of spiroindenes. Additionally, as deduced from the SAR studies, we provide insights regarding the new chemical opportunities that the spiroindolones can offer to the TB drug discovery initiatives.


Assuntos
Antituberculosos/farmacologia , Piperidinas/farmacologia , Compostos de Espiro/farmacologia , Animais , Antituberculosos/síntese química , Antituberculosos/farmacocinética , Bactérias/efeitos dos fármacos , Farmacorresistência Bacteriana/genética , Genoma Bacteriano , Ensaios de Triagem em Larga Escala , Hipóxia , Lipídeos/química , Metaloproteinase 13 da Matriz/biossíntese , Metaloproteinase 13 da Matriz/genética , Camundongos , Testes de Sensibilidade Microbiana , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Piperidinas/síntese química , Piperidinas/farmacocinética , Compostos de Espiro/síntese química , Compostos de Espiro/farmacocinética , Relação Estrutura-Atividade
3.
J Bacteriol ; 196(19): 3441-51, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25049093

RESUMO

The cell envelope of Mycobacterium tuberculosis contains glycans and lipids of peculiar structure that play prominent roles in the biology and pathogenesis of tuberculosis. Consequently, the chemical structure and biosynthesis of the cell wall have been intensively investigated in order to identify novel drug targets. Here, we validate that the function of phosphatidyl-myo-inositol mannosyltransferase PimA is vital for M. tuberculosis in vitro and in vivo. PimA initiates the biosynthesis of phosphatidyl-myo-inositol mannosides by transferring a mannosyl residue from GDP-Man to phosphatidyl-myo-inositol on the cytoplasmic side of the plasma membrane. To prove the essential nature of pimA in M. tuberculosis, we constructed a pimA conditional mutant by using the TetR-Pip off system and showed that downregulation of PimA expression causes bactericidality in batch cultures. Consistent with the biochemical reaction catalyzed by PimA, this phenotype was associated with markedly reduced levels of phosphatidyl-myo-inositol dimannosides, essential structural components of the mycobacterial cell envelope. In addition, the requirement of PimA for viability was clearly demonstrated during macrophage infection and in two different mouse models of infection, where a dramatic decrease in viable counts was observed upon silencing of the gene. Notably, depletion of PimA resulted in complete clearance of the mouse lungs during both the acute and chronic phases of infection. Altogether, the experimental data highlight the importance of the phosphatidyl-myo-inositol mannoside biosynthetic pathway for M. tuberculosis and confirm that PimA is a novel target for future drug discovery programs.


Assuntos
Proteínas de Bactérias/metabolismo , Manosiltransferases/metabolismo , Mycobacterium tuberculosis/enzimologia , Mycobacterium tuberculosis/crescimento & desenvolvimento , Tuberculose/microbiologia , Animais , Proteínas de Bactérias/genética , Feminino , Humanos , Macrófagos/metabolismo , Macrófagos/microbiologia , Manosiltransferases/genética , Camundongos , Camundongos Endogâmicos C57BL , Mycobacterium tuberculosis/genética , Fosfatidilinositóis/biossíntese
4.
Mol Microbiol ; 90(2): 356-66, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23962235

RESUMO

Alpha-ketoglutarate is a key metabolic intermediate at the crossroads of carbon and nitrogen metabolism, whose fate is tightly regulated. In mycobacteria the protein GarA regulates the tricarboxylic acid cycle and glutamate synthesis by direct binding and regulation of three enzymes that use α-ketoglutarate. GarA, in turn, is thought to be regulated via phosphorylation by protein kinase G and other kinases. We have investigated the requirement for GarA for metabolic regulation during growth in vitro and in macrophages. GarA was found to be essential to Mycobacterium tuberculosis, but dispensable in non-pathogenic Mycobacterium smegmatis. Disruption of garA caused a distinctive, nutrient-dependent phenotype, fitting with its proposed role in regulating glutamate metabolism. The data underline the importance of the TCA cycle and the balance with glutamate synthesis in M. tuberculosis and reveal vulnerability to disruption of these pathways.


Assuntos
Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Genes Bacterianos , Ácidos Cetoglutáricos/metabolismo , Mycobacterium smegmatis/genética , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/metabolismo , Linhagem Celular Tumoral , Ciclo do Ácido Cítrico , Regulação Bacteriana da Expressão Gênica , Ácido Glutâmico/metabolismo , Humanos , Macrófagos/microbiologia , Mutagênese Sítio-Dirigida , Mycobacterium smegmatis/metabolismo , Fenótipo , Fosforilação , Proteínas Recombinantes/metabolismo
5.
Microb Biotechnol ; 11(1): 238-247, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29076636

RESUMO

A range of regulated gene expression systems has been developed for mycobacteria in the last few years to facilitate the study of essential genes, validate novel drug targets and evaluate their vulnerability. Among these, the TetR/Pip-OFF repressible promoter system was successfully used in several mycobacterial species both in vitro and in vivo. In the first version of the system, the repressible promoter was Pptr , a strong Pip-repressible promoter of Streptomyces pristinaespiralis, which might hamper effective downregulation of genes with a low basal expression level. Here, we report an enhanced system that allows more effective control of genes expressed at low level. To this end, we subjected Pptr to targeted mutagenesis and produced 16 different promoters with different strength. Three of them, weaker than the wild-type promoter, were selected and characterized showing that they can indeed improve the performances of TetR/Pip-OFF repressible system both in vitro and in vivo increasing its stringency. Finally, we used these promoters to construct a series of bacterial biosensors with different sensitivity to DprE1 inhibitors and developed a whole-cell screening assay to identify inhibitors of this enzyme.


Assuntos
Regulação Bacteriana da Expressão Gênica , Genes Essenciais , Genética Microbiana/métodos , Biologia Molecular/métodos , Mutagênese , Mycobacterium tuberculosis/genética , Regiões Promotoras Genéticas , Oxirredutases do Álcool/antagonistas & inibidores , Proteínas de Bactérias/antagonistas & inibidores , Técnicas Biossensoriais , Inibidores Enzimáticos/análise
6.
Tuberculosis (Edinb) ; 100: 95-101, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27553416

RESUMO

The lack of proper treatment for serious infectious diseases due to the emergence of multidrug resistance reinforces the need for the discovery of novel antibiotics. This is particularly true for tuberculosis (TB) for which 3.7% of new cases and 20% of previously treated cases are estimated to be caused by multi-drug resistant strains. In addition, in the case of TB, which claimed 1.5 million lives in 2014, the treatment of the least complicated, drug sensitive cases is lengthy and disagreeable. Therefore, new drugs with novel targets are urgently needed to control resistant Mycobacterium tuberculosis strains. In this manuscript we report the characterization of the thiopeptide micrococcin P1 as an anti-tubercular agent. Our biochemical experiments show that this antibiotic inhibits the elongation step of protein synthesis in mycobacteria. We have further identified micrococcin resistant mutations in the ribosomal protein L11 (RplK); the mutations were located in the proline loop at the N-terminus. Reintroduction of the mutations into a clean genetic background, confirmed that they conferred resistance, while introduction of the wild type RplK allele into resistant strains re-established sensitivity. We also identified a mutation in the 23S rRNA gene. These data, in good agreement with previous structural studies suggest that also in M. tuberculosis micrococcin P1 functions by binding to the cleft between the 23S rRNA and the L11 protein loop, thus interfering with the binding of elongation factors Tu and G (EF-Tu and EF-G) and inhibiting protein translocation.


Assuntos
Antibióticos Antituberculose/farmacologia , Bacteriocinas/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Peptídeos/farmacologia , Animais , Antibióticos Antituberculose/administração & dosagem , Proteínas de Bactérias/biossíntese , Bacteriocinas/administração & dosagem , Células Cultivadas , Contagem de Colônia Microbiana , Relação Dose-Resposta a Droga , Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos/métodos , Farmacorresistência Bacteriana/genética , Humanos , Macrófagos/microbiologia , Testes de Sensibilidade Microbiana/métodos , Mutação , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/crescimento & desenvolvimento , Mycobacterium tuberculosis/isolamento & purificação , Elongação Traducional da Cadeia Peptídica/efeitos dos fármacos , Peptídeos/administração & dosagem , Proteínas Ribossômicas/genética
7.
PLoS One ; 8(3): e57517, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23469198

RESUMO

PPE represent a peculiar family of mycobacterial proteins characterized by a 180 aminoacids conserved N-terminal domain. Several PPE genes are co-transcribed with a gene encoding for a protein belonging to another family of mycobacterial specific proteins named PE. Only one PE-PPE couple has been extensively characterized so far (PE25-PPE41) and it was shown that these two proteins form a heterodimer and that this interaction is essential for PPE41 stability and translocation through the mycobacterial cell wall. In this study we characterize the PE11-PPE17 couple. In contrast with what was found for PE25-PPE41, we show that PPE17 is not secreted but surface exposed. Moreover, we demonstrate that the presence of PE11 is not necessary for PPE17 stability or for its localization on the mycobacterial surface. Finally, we show that the PPE domain of PPE17 targets the mycobacterial cell wall and that this domain can be used as a fusion partner to expose heterologous proteins on the mycobacterial surface.


Assuntos
Antígenos de Bactérias/genética , Proteínas de Bactérias/genética , Parede Celular/genética , Mycobacterium bovis/genética , Mycobacterium smegmatis/genética , Mycobacterium tuberculosis/genética , Antígenos de Bactérias/metabolismo , Proteínas de Bactérias/metabolismo , Sítios de Ligação , Parede Celular/metabolismo , Expressão Gênica , Mycobacterium bovis/metabolismo , Mycobacterium smegmatis/metabolismo , Mycobacterium tuberculosis/metabolismo , Ligação Proteica , Estabilidade Proteica , Estrutura Terciária de Proteína , Transporte Proteico
8.
Pathog Dis ; 69(3): 232-9, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24106104

RESUMO

PE_PGRSs are a large family of proteins identified in Mycobacterium tuberculosis complex and in few other pathogenic mycobacteria. The PE domain of PE_PGRS33 mediates localization of the protein on the mycobacterial cell surface, where the PGRS domain is available to interact with host components. In this study, PE_PGRS33 and its functional deletion mutants were expressed in M. smegmatis, and in vitro and in vivo assays were used to dissect the protein domains involved in the immunomodulatory properties of the protein. We demonstrate that PE_PGRS33-mediated secretion of TNF-α by macrophages occurs by extracellular interaction with TLR2. Our results also show that while the PGRS domain of the protein is required for triggering TNF-α secretion, mutation in the PE domain affects the pro-inflammatory properties of the protein. These results indicate that PE_PGRS33 is a protein with immunomodulatory activity and that protein stability and localization on the mycobacterial surface can affect these properties.


Assuntos
Antígenos de Bactérias/metabolismo , Proteínas de Bactérias/metabolismo , Proteínas de Membrana/metabolismo , Mycobacterium tuberculosis/imunologia , Domínios e Motivos de Interação entre Proteínas , Animais , Antígenos de Bactérias/química , Antígenos de Bactérias/genética , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Morte Celular/genética , Espaço Extracelular , Feminino , Expressão Gênica , Imunomodulação , Macrófagos/imunologia , Macrófagos/metabolismo , Macrófagos/microbiologia , Proteínas de Membrana/química , Proteínas de Membrana/genética , Camundongos , Camundongos Knockout , Mutação , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/metabolismo , Ligação Proteica , Domínios e Motivos de Interação entre Proteínas/genética , Esplenomegalia/genética , Esplenomegalia/metabolismo , Esplenomegalia/patologia , Receptor 2 Toll-Like/genética , Receptor 2 Toll-Like/metabolismo , Fator de Necrose Tumoral alfa/biossíntese
9.
PLoS One ; 6(11): e27713, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22110736

RESUMO

PE are peculiar exported mycobacterial proteins over-represented in pathogenic mycobacterial species. They are characterized by an N-terminal domain of about 110 amino acids (PE domain) which has been demonstrated to be responsible for their export and localization. In this paper, we characterize the PE domain of PE_PGRS33 (PE(Rv1818c)), one of the best characterized PE proteins. We constructed several mutated proteins in which portions of the PE domain were deleted or subjected to defined mutations. These proteins were expressed in different mycobacterial species and their localization was characterized. We confirmed that the PE domain is essential for PE_PGRS33 surface localization, and demonstrated that a PE domain lacking its first 30 amino acids loses its function. However, single amino acid substitutions in two regions extremely well conserved within the N-terminal domain of all PE proteins had some effect on the stability of PE_PGRS33, but not on its localization. Using Mycobacterium marinum we could show that the type VII secretion system ESX-5 is essential for PE_PGRS33 export. Moreover, in M. marinum, but not in Mycobacterium bovis BCG and in Mycobacterium tuberculosis, the PE domain of PE_PGRS33 is processed and secreted into the culture medium when expressed in the absence of the PGRS domain. Finally, using chimeric proteins in which different portions of the PE(Rv1818c) domain were fused to the N-terminus of the green fluorescent protein, we could hypothesize that the first 30 amino acids of the PE domain contain a sequence that allows protein translocation.


Assuntos
Proteínas de Bactérias/química , Proteínas de Bactérias/metabolismo , Parede Celular/metabolismo , Mycobacterium/citologia , Mycobacterium/metabolismo , Substituição de Aminoácidos , Proteínas de Bactérias/genética , Espaço Intracelular/metabolismo , Mutação , Estabilidade Proteica , Estrutura Terciária de Proteína , Transporte Proteico , Especificidade da Espécie
10.
Neurotoxicology ; 31(5): 509-17, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20685220

RESUMO

Cuprizone is used to obtain demyelination in mice. Cuprizone-treated mice show symptoms similar to several neurodegenerative disorders such as severe status spongiosus. Although it has a simple chemical formula, its neurotoxic mechanism is still unknown. In this work, we examined both physico-chemical properties and biological effects of cuprizone. Our results indicate that cuprizone has very complicated and misunderstood solution chemistry. Moreover, we show here the inability of cuprizone to cross neither the intestinal epithelial barrier nor the neuronal cell membrane, as well its high tolerability by cultured neurons. If added to mice diet, cuprizone does not accumulate in liver or in brain. Therefore, its neurotoxic effect is explainable only in terms of its capability to chelate copper, leading to chronic copper deficiency.


Assuntos
Cobre/deficiência , Cuprizona/toxicidade , Inibidores da Monoaminoxidase/toxicidade , Degeneração Neural/etiologia , Síndromes Neurotóxicas , Animais , Encéfalo/metabolismo , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Permeabilidade da Membrana Celular/efeitos dos fármacos , Permeabilidade da Membrana Celular/fisiologia , Ceruloplasmina/efeitos dos fármacos , Fenômenos Químicos , Cobre/metabolismo , Cuprizona/química , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Humanos , Fígado/metabolismo , Espectrometria de Massas/métodos , Camundongos , Inibidores da Monoaminoxidase/química , Degeneração Neural/metabolismo , Neuroblastoma , Síndromes Neurotóxicas/complicações , Síndromes Neurotóxicas/etiologia , Síndromes Neurotóxicas/metabolismo , Oxirredutases/metabolismo , Espectrofotometria Atômica/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA